Aytu BioPharma, Inc. (LON:0A8M)

Market Cap	15.24M
Revenue (ttm)	63.20M
Net Income (ttm)	1.27M
Shares Out	n/a
EPS (ttm)	-0.64
PE Ratio	12.02
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	39,135
Average Volume	2,207
Open	2.200
Previous Close	1.680
Day's Range	2.200 - 2.200
52-Week Range	1.340 - 3.240
Beta	n/a
RSI	71.86
Earnings Date	Sep 26, 2025

About Aytu BioPharma

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above, and Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Kar...

• Industry: Biological Products, Except Diagnostic Substances
• CEO: Joshua Disbrow
• Employees: 102
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A8M

Financial Performance

In 2024, Aytu BioPharma's revenue was $81.00 million, a decrease of -24.58% compared to the previous year's $107.40 million. Losses were -$15.84 million, -7.08% less than in 2023.

Financial numbers in USD